Cargando…

Factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis: Results from the Institute of Rheumatology Rheumatoid Arthritis cohort study

OBJECTIVES: This study aimed to evaluate factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis (RA). METHODS: Patients with RA who enrolled in our cohort completed self-administered questionnaires which included questions regarding their osteoporosis medi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakayama, Masanori, Furuya, Takefumi, Inoue, Eisuke, Tanaka, Eiichi, Ikari, Katsunori, Taniguchi, Atsuo, Yamanaka, Hisahi, Harigai, Masayoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Osteoporosis 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374244/ https://www.ncbi.nlm.nih.gov/pubmed/32715099 http://dx.doi.org/10.1016/j.afos.2020.04.003

Ejemplares similares

A GC polymorphism associated with serum 25-hydroxyvitamin D level is a risk factor for hip fracture in Japanese patients with rheumatoid arthritis: 10-year follow-up of the Institute of Rheumatology, Rheumatoid Arthritis cohort study
por: Yoshida, Shinji, et al.
Publicado: (2014)

An Osteoprotegerin Gene Polymorphism Is Associated with an Increased Risk of Hip Fracture in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Observational Cohort Study
por: Yoshida, Shinji, et al.
Publicado: (2014)

Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data
por: Tanaka, Eiichi, et al.
Publicado: (2022)

Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese
por: Shirai, Yuya, et al.
Publicado: (2020)

Features of patients with rheumatoid arthritis whose debut joint is a foot or ankle joint: A 5,479-case study from the IORRA cohort
por: Yano, Koichiro, et al.
Publicado: (2018)

ITGAV polymorphism and disease susceptibility in a Japanese rheumatoid arthritis population
por: Iikuni, Noriko, et al.
Publicado: (2007)

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Response to ‘Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study’
por: Ikari, Katsunori, et al.
Publicado: (2014)

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
por: Takeuchi, Tsutomu, et al.
Publicado: (2018)

Functional Variants in NFKBIE and RTKN2 Involved in Activation of the NF-κB Pathway Are Associated with Rheumatoid Arthritis in Japanese
por: Myouzen, Keiko, et al.
Publicado: (2012)

Time-averaged disease activity fits better joint destruction in rheumatoid arthritis
por: Tsuji, Hideaki, et al.
Publicado: (2017)

Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study
por: Sakai, Ryoko, et al.
Publicado: (2022)

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
por: Koike, Ryuji, et al.
Publicado: (2009)

Osteoporosis diagnostics in patients with rheumatoid arthritis
por: Węgierska, Małgorzata, et al.
Publicado: (2016)

Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons
por: Llorente, Irene, et al.
Publicado: (2020)

Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis
por: Pietschmann, Peter, et al.
Publicado: (2022)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis
por: Vassilopoulos, Dimitrios, et al.
Publicado: (2020)

Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
por: Koike, Takao, et al.
Publicado: (2011)

Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis
por: Kim, Yunkyung, et al.
Publicado: (2023)

Osteoporosis in Black South Africans With Rheumatoid Arthritis
por: Naidoo, Tania, et al.
Publicado: (2023)

Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs
por: Sugihara, Takahiko, et al.
Publicado: (2016)

Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis
por: Fukuda, Shin, et al.
Publicado: (2014)

The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis
por: Mastrangelo, Andrea, et al.
Publicado: (2015)

Association Between the Extent of Periodontal Inflammation and the Severity of Rheumatoid Arthritis in Japanese Patients With Rheumatoid Arthritis
por: Hashimoto, Hiroko, et al.
Publicado: (2021)

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study
por: Mochizuki, Takeshi, et al.
Publicado: (2021)

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
por: Kihara, Mari, et al.
Publicado: (2016)

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Joint-Preserving Surgery for Forefoot Deformities in Patients with Rheumatoid Arthritis: A Literature Review
por: Yano, Koichiro, et al.
Publicado: (2021)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
por: Yokoyama-Kokuryo, Waka, et al.
Publicado: (2020)

Application of cellular gene therapy for rheumatoid arthritis
por: Nakajima, Atsuo
Publicado: (2006)

Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis
por: Tomizawa, T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f77oo5lv17ld4id7cvguseo91l